Patient Related Outcome Measures Dovepress Meta-analysis Provides Evidence-based Interpretation Guidelines for the Clinical Significance of Mean Differences for the Fact-g, a Cancer-specific Quality of Life Questionnaire
暂无分享,去创建一个
D. Osoba | M. Stockler | D. Cella | D. Eton | M. King | A. Eisenstein | Joanna Thompson
[1] D. Osoba,et al. Meta-analysis provides evidence-based effect sizes for a cancer-specific quality-of-life questionnaire, the FACT-G. , 2010, Journal of clinical epidemiology.
[2] Xiao-Hua Zhou,et al. Statistical Methods for Meta‐Analysis , 2008 .
[3] P. Fayers,et al. The clinical significance of adaptation to changing health: A meta-analysis of response shift , 2006, Quality of Life Research.
[4] D. Cella,et al. Quality of life (QOL) outcomes from a randomized trial of cisplatin versus cisplatin plus paclitaxel in advanced cervical cancer: a Gynecologic Oncology Group study. , 2006, Gynecologic oncology.
[5] D. Eton,et al. Combining Distribution- and Anchor-Based Approaches to Determine Minimally Important Differences , 2005, Evaluation & the health professions.
[6] G. Guyatt,et al. Measurement Properties and Interpretability of the Chronic Respiratory Disease Questionnaire (CRQ) , 2005, COPD.
[7] D. Neuberg,et al. A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. , 2004, Journal of clinical epidemiology.
[8] Galina Velikova,et al. Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] R. Larson,et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] G. Norman,et al. Interpretation of Changes in Health-related Quality of Life: The Remarkable Universality of Half a Standard Deviation , 2003, Medical care.
[11] D. Cella,et al. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. , 2002, Journal of pain and symptom management.
[12] L. Fallowfield,et al. Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy , 2002, British Journal of Cancer.
[13] Gordon H Guyatt,et al. Methods to explain the clinical significance of health status measures. , 2002, Mayo Clinic proceedings.
[14] David Cella,et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. , 2002, Journal of the National Cancer Institute.
[15] D H Gustafson,et al. Impact of surgery and chemotherapy on the quality of life of younger women with breast carcinoma , 2001, Cancer.
[16] M. Mehta,et al. QUALITY OF LIFE ASSESSMENT IN ADVANCED NON-SMALL-CELL LUNG CANCER PATIENTS UNDERGOING AN ACCELERATED RADIOTHERAPY REGIMEN: REPORT OF ECOG STUDY 4593 , 2001 .
[17] D. Gustafson,et al. Effect of computer support on younger women with breast cancer , 2001, Journal of General Internal Medicine.
[18] D. Cella,et al. Outpatient taxol and carboplatin chemotherapy for suboptimally debulked epithelial carcinoma of the ovary results in improved quality of life: an Eastern Cooperative Oncology Group Phase II Study (E2E93). , 2001, Cancer journal.
[19] M. Kris,et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] K. Pienta,et al. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. , 1997, Urology.
[21] M. King. The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30 , 1996, Quality of Life Research.
[22] D. Cella,et al. The influence of stress management training in HIV disease. , 1996, Nursing research.
[23] R. Epstein,et al. Interpretation of quality of life changes , 1993, Quality of Life Research.
[24] D. Osoba,et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.
[25] D. Tulsky,et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] J. Cutler,et al. Variance imputation for overviews of clinical trials with continuous response. , 1992, Journal of clinical epidemiology.
[27] G. Guyatt,et al. Measurement of health status. Ascertaining the minimal clinically important difference. , 1989, Controlled clinical trials.
[28] J. R. Landis,et al. The measurement of observer agreement for categorical data. , 1977, Biometrics.
[29] Constantine Gatsonis,et al. Analysing and Presenting Results , 2010 .
[30] D. Cella,et al. Group versus individual approaches to understanding the clinical significance of differences or changes in quality of life , 2002 .
[31] M. Mehta,et al. Quality of life assessment in advanced non-small-cell lung cancer patients undergoing an accelerated radiotherapy regimen: report of ECOG study 4593. Eastern Cooperative Oncology Group. , 2001, International journal of radiation oncology, biology, physics.
[32] D. Machin,et al. A clinical model for quality of life assessment in cancer patients receiving chemotherapy. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[33] D. Cella,et al. RTOG's first quality of life study--RTOG 90-20: a phase II trial of external beam radiation with etanidazole for locally advanced prostate cancer. , 1995, International journal of radiation oncology, biology, physics.